Updated result (January 26, 2026): Roche announced full 48-week Phase II results from the CT388-103 trial (NCT06525935, n=469)
However, retatrutide takes it one step further, also acting as a glucagon receptor agonist
if more than 3 days, skip that dose Daily GLP-1s: If you miss a dose, follow your PIL instructions If you take insulin or sulfonylureas alongside GLP-1 medications, do not adjust these doses yourself without medical advice, as this could increase hypoglycaemia risk Report persistent side effects to your GP rather than stopping treatment abruptly Some patients may require dose adjustment if they develop acute illness, undergo surgery, or experience significant changes in kidney function
Now, science has finally caught up
While other reviews have described the MACE risk reduction in the general population with T2DM [23, 24], non-T2DM [25], or both [26], the present study seeks to address the gap in the literature in providing a comprehensive meta-analysis on the number need to treat (NNT), efficacy and safety profile of GLP-1RA in reducing the risk of myocardial infarction (MI) and individual ASCVD constituents, namely non-fatal MI, unstable angina, coronary revascularization, and/or cardiovascular mortality
